MOONWALK
Live / Applied — Second extension granted (statement of use) (as of 06 Feb 2026)
What this means for you
Not registered yet, but its 02 Oct 2023 filing date beats anything filed after it. If it registers, the owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 98206132
- Mark type
- Word mark
- Filed
- 02 Oct 2023
- Published for opposition
- 07 Jan 2025
- Attorney of record
- Michael J. Allan
Goods and services
- Class 005 — Pharmaceuticals: Pharmaceutical preparations and substances for the treatment of autoimmune, cardiometabolic, cardiovascular, dermatological, endocrine, epigenetic, gastrointestinal, genetic, hematological, hemoglobinopathy, immunological, infectious, liver, metabolic, muscular dystrophy, neurodegenerative, neuropsychiatric, oncological, ophthalmological, psychiatric, pulmonary, renal, reproductive, respiratory, and skeletal diseases, age-related diseases in the nature of neurodegeneration, arthritis, cardiovascular disease, type 2 diabetes, cancer, and osteoporosis, and pediatric diseases in the nature of anemia, asthma, gastrointestinal disorders, skin conditions, neurological disorders, blood disorders, endocrine disorders, developmental or growth disorders, immunological disorders, obesity, and type 1 diabetes; Veterinary pharmaceutical preparations and substances for the treatment of autoimmune, cardiometabolic, cardiovascular, dermatological, endocrine, epigenetic, gastrointestinal, genetic, hematological, hemoglobinopathy, immunological, infectious, liver, metabolic, muscular dystrophy, neurodegenerative, neuropsychiatric, oncological, ophthalmological, pulmonary, renal, reproductive, respiratory, and skeletal diseases, and age-related diseases in the nature of arthritis, thyroid imbalance, heart disease, kidney disease, cancer, endocrine disorders, liver disease, obesity, skin, respiratory, gastrointestinal and dental disease
Owner
- Moonwalk Biosciences, South San Francisco, CA, US
- Moonwalk Biosciences, South San Francisco, CA, US
Prosecution history
- 06 Feb 2026 — SOU EXTENSION 2 GRANTED
- 04 Feb 2026 — SOU EXTENSION 2 FILED
- 05 Feb 2026 — SOU TEAS EXTENSION RECEIVED
- 03 Jan 2026 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 02 Jan 2026 — CORRECTED NOA E-MAILED
- 02 Jan 2026 — SOU EXTENSION 1 GRANTED
- 10 Jul 2025 — SOU EXTENSION 1 FILED
- 02 Jan 2026 — DIVISIONAL PROCESSING COMPLETE
- 11 Jul 2025 — DIVISIONAL REQUEST RECEIVED
- 02 Jan 2026 — CASE ASSIGNED TO INTENT TO USE PARALEGAL
- 11 Jul 2025 — TEAS REQUEST TO DIVIDE RECEIVED
- 04 Mar 2025 — NOA E-MAILED - SOU REQUIRED FROM APPLICANT
- 07 Jan 2025 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 07 Jan 2025 — PUBLISHED FOR OPPOSITION
- 01 Jan 2025 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED